EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Transgenic amyloid precursor protein mouse models of amyloidosis. Incomplete models for Alzheimer's disease but effective predictors of anti‐amyloid therapies

David G Morgan iD, Bruce T Lamb

Alzheimer's & Dementia · 2024

DOI: 10.1002/alz.13566 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2024. Verfasst von David G Morgan und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Neuroscience, and Alzheimer's Alliance, College of Human Medicine, Michigan State University, Grand Rapids, Michigan, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Amyloidosis, Cognitive Dysfunction. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION Amyloid precursor protein (APP) transgenic mice are models of Alzheimer's disease (AD) amyloidosis, not all of AD. Diffuse, compacted, and vascular deposits in APP mice mimic those found in AD cases. METHODS Most interventional studies in APP mice start treatment early in the process of amyloid deposition, consistent with a prevention treatment regimen. Most clinical trials treat patients with established amyloid deposits in a therapeutic treatment regimen. RESULTS The first treatment to reduce amyloid and cognitive impairment in mice was immunotherapy. The APP mouse models not only predicted efficacy, but presaged the vascular leakage called ARIA. The recent immunotherapy clinical trials that removed amyloid and slowed cognitive decline confirms the utility of these early APP models when used in therapeutic designs. DISCUSSION New mouse models of AD pathologies will add to the research armamentarium, but the early models have accurately predicted responses to amyloid therapies in humans.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseAmyloidosisCognitive DysfunctionHumansMiceAnimalsAmyloid beta-Protein PrecursorMice, TransgenicDisease Models, AnimalAmyloid beta-PeptidesPlaque, Amyloid

Stichwörter der Autor:innen

ARIABACE inhibitorsamyloidimmunotherapymouse modelsprevention studiestherapeutic studiestransgenic mice

Substanzen

Amyloid beta-Protein PrecursorAmyloid beta-Peptides

Autor:innen und Institutionen

  • Department of Translational Neuroscience, and Alzheimer's Alliance, College of Human Medicine, Michigan State University, Grand Rapids, Michigan, USA.
  • Department of Medical and Molecular Genetics, Stark Neurosciences Research Institute, Indianapolis, Indiana, USA.

ORCID-Profile: David G Morgan

Förderung

  • NIA NIH HHS

Zitieren

APA

Morgan, D. G., & Lamb, B. T. (2024). Transgenic amyloid precursor protein mouse models of amyloidosis. Incomplete models for Alzheimer's disease but effective predictors of anti‐amyloid therapies. Alzheimer's & Dementia. https://doi.org/10.1002/alz.13566

Vancouver

Morgan DG, Lamb BT. Transgenic amyloid precursor protein mouse models of amyloidosis. Incomplete models for Alzheimer's disease but effective predictors of anti‐amyloid therapies. Alzheimer's & Dementia. 2024. doi:10.1002/alz.13566

BibTeX
@article{Morgan2024,
  author = {Morgan, David G and Lamb, Bruce T},
  title = {Transgenic amyloid precursor protein mouse models of amyloidosis. Incomplete models for Alzheimer's disease but effective predictors of anti‐amyloid therapies},
  journal = {Alzheimer's & Dementia},
  year = {2024},
  doi = {10.1002/alz.13566}
}
Kostenlos starten →